FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

|--|

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average	burden								
hours per response	: 0.5								

							. ,				. ,								
Name and Address of Reporting Person* Khattar Jack A.					2. Issuer Name and Ticker or Trading Symbol scPharmaceuticals Inc. [SCPH]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
													X	Directo	or		10% Ov	/ner	
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year) 06/06/2023									Officer below)	(give title		Other (s below)	pecify	
C/O SCI	PHARMAC	EUTICALS INC	С		4 If	A 16 Amountment Date of Original Filed (Month/Dat/A/a-a)								C. Individual or Inint/Crown Filing (Charles Assistants					
2400 DI	STRICT AV	/ENUE, SUITE	310		4. 11	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line)					
,														Х	X Form filed by One Reporting Person				
(Street)	ICTON M	ΓΛ	01003												Form fi Persor	iled by More า	thar	one Repo	rting
BUKLIN	IGTON M	IA	01803			1. 4	101.5	4 (.)	.										
-					Ru	Rule 10b5-1(c) Transaction Indication													
(City)	(S	itate)	(Zip)		16.	Check this house indicate that a transcation was made assessed to contract instruction or written also that is instructed to													
						Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
			_									_							
		Tab	le I - Non	ı-Deriv	ative	Sec	curities	s Ac	quired, D	isp	osed c	of, or Be	enefic	ially	/ Owned	t			
1. Title of	Security (Ins	tr. 3)		2. Transa	action				3.										7. Nature
				Date (Month/E	Day/Yea	ay/Year) if any		on Date,	Transacti Code (Ins		ed Of (D) (Instr. 3,		4 and Securitie Benefici					of Indirect Beneficial	
(-	(Month/Day		ıy/Year)	r) 8)										Ownership (Instr. 4)	
							Code	v	Amount	(A) (or Pri	ce	Transact	Transaction(s) (Instr. 3 and 4)		1	1130.4)		
					Code V Amount (D)								(Instr. 3	and 4)					
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of	2.	3. Transaction	3A. Deeme	d			E Numb	30r	6 Data Eval	roical	ble and	7 Title ar	vd.	Ť,	B. Price of	9. Number	of	10.	11. Nature
Derivative Security (Instr. 3)	Conversion or Exercise Price of Derivative Security	Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Securi (Instr. 3 and 4)		Derivative Security (Instr. 5)		derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	у	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	of Indirect Beneficial Ownership (Instr. 4)
													Amou	nt					
									Date		piration		Numb	er					
				- -	Code	v	(A)	(D)	Exercisable			Title	Share	s					
Stock Option (Right to	\$11.71	06/06/2023			A		17,300		(1)	06.	/06/2033	Common Stock	17,3	00	\$0.00	17,300		D	

Explanation of Responses:

1. This stock option vests in full upon the earlier of (i) June 6, 2024, or (ii) the next annual meeting of the Issuer's stockholders.

Remarks:

Exhibit 24 - Power of Attorney.

/s/ John H. Tucker, attorney-in-06/08/2023 fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

With respect to holdings of and transactions in securities issued by scPharmaceuticals Inc. (the "Company"), the undersigned hereby constitutes and appoints the individuals named on Schedule A attached hereto and as may be amended from time to time, or any of them signing singly, with full power of substitution and resubstitution, to act as the undersigned's true and lawful attorney-in-fact to:

- 1. prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the United States Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain and/or regenerate codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934, as amended, or any rule or regulation of the SEC;
- execute for and on behalf of the undersigned, Forms 3, 4, and 5 2. in accordance with Section 16 of the Securities Exchange Act of 1934, as amended, and the rules thereunder;
- 3. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and
- 4. take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution and resubstitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorneys-in-fact substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted.

The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 5th day of June, 2023.

> Signature: /s/ Jack A. Khattar Print Name: Jack A. Khattar

Schedule A

Individuals Appointed as Attorney-in-Fact with Full Power of Substitution and Resubstitution

- John H. Tucker
 Rachael Nokes